- Home
- KROS vs VNDA Comparison
KROS vs VNDA Comparison
Compare KROS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | VNDA |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | 533 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 231.0M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KROS | VNDA |
|---|---|---|
| Price | $9.28 | $3.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $19.83 | $11.50 |
| AVG Volume (30 Days) | 146.3K | ★ 1.2M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $243,864,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $12.05 |
| Revenue Next Year | N/A | $30.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.69 | $3.64 |
| 52 Week High | $22.55 | $9.91 |
Technical Indicators
Market Signals| Indicator | KROS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 39.07 |
| Support Level | N/A | N/A |
| Resistance Level | $11.86 | $5.49 |
| Average True Range (ATR) | 0.58 | 0.27 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 15.14 | 25.12 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.